Announcement • Jul 31
Purple Biotech Ltd, Annual General Meeting, Sep 08, 2026 Purple Biotech Ltd, Annual General Meeting, Sep 08, 2026. Location: co. offices, Israel Announcement • Jun 13
Purple Biotech Presents New Preclinical Data At Eacr 2026 Highlighting Im1240’S Anti-Tumor Activity, Favorable Safety and Pharmacokinetic Profile, and Broad Therapeutic Window Purple Biotech Ltd. announced the presentation of new preclinical data from its lead CAPTN-3 program, IM1240, at the European Association for Cancer Research (EACR) 2026 Annual Congress, being held June 8-11, 2026, in Budapest, Hungary. A non-GLP toxicology study in non-human primates (NHPs) validates the CAPTN-3 masking strategy and supports the planned advancement of IM1240 toward a first-in-human clinical study in 2027. Efficacy data in patient-derived samples from PD-1-resistant head and neck squamous cell carcinoma (HNSCC) metastatic lymph nodes, NSCLC and bladder cancer, generated in collaboration with the laboratory of Dr. Amir Horowitz at the Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai, highlight the essential role of the NKG2A arm in IM1240-mediated anti-tumor immunity and further strengthen CAPTN-3’s differentiation and clinical potential. IM1240 induced apoptosis of PD-1-resistant patient-derived biopsies from six HNSCC metastatic lymph node samples and one enfortumab vedotin/pembrolizumab-resistant muscle-invasive bladder cancer sample, with both the CD3 and NKG2A functional arms required for full activity. In a PD-1/chemotherapy-resistant NSCLC patient-derived explant, IM1240 induced mature tertiary lymphoid structures (TLS) – immune cell organizations associated with effective anti-tumor immunity and favorable clinical prognosis – while increasing CD8 T cell and NK cell abundance and reducing regulatory T cells (Tregs) and tumor cells. These effects were not observed with IM1340, the NKG2A loss-of-function variant, underscoring the essential and differentiated contribution of the NKG2A arm. In a non-GLP dose-range finding toxicology study in NHPs, IM1240 demonstrated markedly superior pharmacokinetics (PK) compared to the non-capped variant IM1222, including an approximately 8-fold longer half-life and 16-fold greater systemic exposure. IM1240 showed dose-proportional PK with a broad therapeutic window, as systemic exposure associated with tumor regression in mouse models remained well below the tolerated levels in NHPs. The CAPTN-3 masking strategy effectively mitigated peripheral T-cell activation and prevented systemic cytokine release in NHPs, which is associated with one of the main safety challenges of T-cell engagers, cytokine release syndrome (CRS). IM1240 induced minimal IL-6 and TNF-a at 10 mg/kg dose, whereas the non-capped IM1222 induced robust cytokine release at just 0.03 mg/kg – a more than 300-fold difference in the dose required to trigger cytokine release. The IM1240 capping design also improved the PK profile by reducing the CD3-mediated antigen sink effect and incorporating human serum albumin to further extend half-life, as compared to the non-capped variant IM1222. IM1240 demonstrated ~14-fold slower clearance than active non-capped IM1222, supporting extended exposure and potential efficacy; rapid clearance of peripherally released non-capped IM1222 reduces systemic accumulation and lowers CRS risk and off-tumor toxicity. Announcement • Apr 30
Purple Biotech Ltd Announces New Preclinical Data Supporting Clinical Potential of Im1240 Captn-3 Tri-Specific Antibody Purple Biotech Ltd. announced new preclinical data supporting the clinical potential of IM1240, the Company’s lead CAPTN-3 tri-specific antibody. Data, generated in the lab of Dr. Amir Horowitz of the Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai, demonstrated that all tested patient-derived tumor samples (n=7) responded to IM1240 treatment. New data shows that the NKG2A arm significantly enhanced anti-tumor activity in all samples and improved the therapeutic index. Immune cell structures known as a hallmark of effective anti-tumor immune response and favorable prognosis, were induced by IM1240 in a patient-derived non-small cell lung cancer (NSCLC) biopsy, corresponding with IM1240 anti-tumor efficacy. The new data, generated in the laboratory of Dr. Amir Horowitz of the Tisch Cancer Institute and the Lipschultz Precision Immunology Institute at the Icahn School of Medicine at Mount Sinai, demonstrated potent anti-tumor activity for IM1240 across multiple treatment-resistant patient-derived tumor samples. All seven tested samples responded to IM1240 treatment, including samples from PD-1 or PD-1/chemo-resistant head and neck squamous cell carcinoma metastatic lymph nodes and enfortumab vedotin + PD-1-resistant muscle-invasive bladder cancer. Further tissue profiling analyses of NSCLC patient-derived explants demonstrated that treatment with IM1240 induced pronounced immune cell reorganization within the tissue hallmarked by visible induction of mature tertiary lymphoid structures (TLS), which are associated with strong anti-tumor immunity and improved clinical outcomes, as well as increased abundances of CD8 T cells and NK cells, and reduction in numbers of Tregs and tumor cells. CAPTN-3, Purple Biotech's lead program, is a platform of masked tri-specific antibodies that simultaneously target tumor-associated antigens while engaging both T cells and NK cells. Proprietary capping technology confines immune activation to the tumor microenvironment by masking the CD3-binding arm in circulation and activating it only at the tumor site, significantly expanding the therapeutic window versus unmasked T-cell engagers. The platform’s lead candidates, IM1240 (targeting 5T4) and IM1305 (targeting TROP2), are in preclinical development. The Company’s pipeline also includes additional clinical-stage assets, for which further development is pending partnering or investment, including CM24, a CEACAM1-blocking antibody that demonstrated improved outcomes across all efficacy endpoints in a Phase 2 study for the treatment of pancreatic ductal adenocarcinoma, and NT219, a dual IRS1/2 and STAT3 inhibitor in a Phase 2 study for the treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck. 
